We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image

INDIA IMMUNO-ONCOLOGY DRUGS MARKET ANALYSIS

India Immuno-Oncology Drugs Market, by Drug Type (Immune Checkpoint Inhibitors (Nivolumab, Atezolimumab, Pembrolizumab, Durvalumab), Monoclonal Antibodies (Rituximab, Trastazumab, Bevacizumab , Nimotuzumab, Pertuzumab, Ado-Trastuzumab Emtansine ), and Cancer Vaccines (Gardasil, Cervarix), by Cancer Type (Lung Cancer, Blood Cancer, Breast Cancer, Ovarian Cancer, Cervical Cancer, Colorectal Cancer, Stomach Cancer, Head & Neck Cancer, and Others), and by Distribution Channel (Online Pharmacies, Retail Pharmacies, and Hospital Pharmacies) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

  • Published In : Aug 2023
  • Code : CMI2631
  • Pages :162
  • Formats :
      Excel and PDF
  • Industry : Pharmaceutical

India Immuno-Oncology Drugs MarketSize and Trends

India immuno-oncology drugs market is estimated to be valued at US$ 265 Mn in 2021 and is expected to exhibit a CAGR of 13.1% during the forecast period (2021 -2028).

Figure 1. India Immuno-Oncology Drugs Market (US$ Mn), By Drug Type, 2021

Figure 1.1. India Immuno-Oncology Drugs Market (US$ Mn), By Drug Type, 2028

The increasing developments and product launches are expected to drive the market growth over the forecast period.

India Immuno-Oncology Drugs Market – Impact of Coronavirus (Covid-19) Pandemic

The coronavirus (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. The shutdown disrupted the supply, distribution, and manufacturing of medical supplies globally. Moreover due to social distancing, footfall in clinics and health institutions was observed which has led to a decrease in the number of surgical procedures, clinical trials, research and development activities, and others, which has negatively impacted the market growth.

Market Trends: Increasing developments and product launches

For instance, researchers from Tata Centre for Technology and Design, IIT Bombay, are currently working on developing indigenous CAR T-cell therapy, affordable to cancer patients in the India.

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Credibility and Certifications

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Credibility and Certifications

27001:2022

Credibility and Certifications

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.